Ulcerative Colitis: The Complete Guide to Medical Management serves as the definitive source for medical management of ulcerative colitis (UC). Dr. Gary R. Lichtenstein, along with Dr. Ellen J. Scherl, have collaborated with over 60 experts from around the world to provide gastroenterologists and those in training with the necessary information to successfully manage the patient with ulcerative colitis. Sections Include: • General o The role of the FDA in drug development; pediatric considerations; disease modifiers; and more • Medications o Antibiotic use in treatment of UC; oral novel biological therapies for UC; calcineurin inhibitors use in UC; novel biologic and non-biologic therapy for UC; and more • Specific Clinical Presentations o Medical management of toxic megacolon; management of extraintestinal manifestations; medical therapy of left-sided UC; use of prebiotics and probiotics; maintenance of remission; and more Features: • Color images, graphs, and tables • Extensive index that includes cross-referencing to Crohn’s Disease: The Complete Guide to Medical Management • Comprehensive references at the end of each chapter Organized into an easy-to-reference format, Ulcerative Colitis: The Complete Guide to Medical Management threads theory into practice and provides gastroenterology professionals with the most comprehensive information available. The other side of inflammatory bowel disease is covered in Drs. Gary R. Lichtenstein and Ellen J. Scherl’s Crohn’s Disease: The Complete Guide to Medical Management. All gastroenterologists will find both books to be essential for future practice in the treatment and care of their patients with either Crohn’s disease or ulcerative colitis, as well as in the overall management of those with inflammatory bowel disease.
Provides detailed clinical guidance on the management of ulcerative colitis by disease severity. Clinical presentation and diagnosis criteria are presented along with epidemiology, etiopathogenesis and environmental risk factors. The book contains the 2019 American College of Gastroenterology Ulcerative Colitis Treatment Guidelines. Disease management based on disease severity with separate chapters are devoted to each class of medications including aminosalicylate, corticosteroids, immunomodulators, and biologics. Comorbidities are reviewed in detail as is health maintenance for the ulcerative colitis patient.
Crohn’s Disease: The Complete Guide to Medical Management serves as the definitive source for medical management of Crohn’s Disease (CD). Dr. Gary R. Lichtenstein, along with Dr. Ellen J. Scherl, have collaborated with over 60 experts from around the world to provide gastroenterologists and those in training with the necessary information to successfully manage the patient with Crohn’s disease. Sections Include: • General o The role of the FDA in drug development; pediatric considerations; disease modifiers; and more • Medications o Antibiotic use in treatment of CD; oral budesonide; infliximab; novel biological and non biologic therapies for CD; and more • Specific Clinical Scenarios o Management of steroid unresponsive CD; management of enteric fistulae; use of pre- and probiotics; medical management of short bowel syndrome; maintenance therapy of CD; and more Features: • Color images, graphs, and tables • Extensive index that includes cross-referencing to Ulcerative Colitis: The Complete Guide to Medical Management • An appendix on Infliximab treatment • Comprehensive references at the end of each chapter Organized into an easy-to-reference format, Crohn’s Disease: The Complete Guide to Medical Management threads theory into practice and provides Gastroenterology professionals with the most comprehensive information available on this disease state. The other side of inflammatory bowel disease is covered in Drs. Gary R. Lichtenstein and Ellen J. Scherl’s Ulcerative Colitis: The Complete Guide to Medical Management. All gastroenterologists will find both books to be essential for future practice in the treatment and care of their patients with either Crohn’s disease or ulcerative colitis, as well as in the overall management of those with inflammatory bowel disease.
Ulcerative Colitis: The Complete Guide to Medical Management serves as the definitive source for medical management of ulcerative colitis (UC). Dr. Gary R. Lichtenstein, along with Dr. Ellen J. Scherl, have collaborated with over 60 experts from around the world to provide gastroenterologists and those in training with the necessary information to successfully manage the patient with ulcerative colitis. Sections Include: • General o The role of the FDA in drug development; pediatric considerations; disease modifiers; and more • Medications o Antibiotic use in treatment of UC; oral novel biological therapies for UC; calcineurin inhibitors use in UC; novel biologic and non-biologic therapy for UC; and more • Specific Clinical Presentations o Medical management of toxic megacolon; management of extraintestinal manifestations; medical therapy of left-sided UC; use of prebiotics and probiotics; maintenance of remission; and more Features: • Color images, graphs, and tables • Extensive index that includes cross-referencing to Crohn’s Disease: The Complete Guide to Medical Management • Comprehensive references at the end of each chapter Organized into an easy-to-reference format, Ulcerative Colitis: The Complete Guide to Medical Management threads theory into practice and provides gastroenterology professionals with the most comprehensive information available. The other side of inflammatory bowel disease is covered in Drs. Gary R. Lichtenstein and Ellen J. Scherl’s Crohn’s Disease: The Complete Guide to Medical Management. All gastroenterologists will find both books to be essential for future practice in the treatment and care of their patients with either Crohn’s disease or ulcerative colitis, as well as in the overall management of those with inflammatory bowel disease.
Crohn’s Disease: The Complete Guide to Medical Management serves as the definitive source for medical management of Crohn’s Disease (CD). Dr. Gary R. Lichtenstein, along with Dr. Ellen J. Scherl, have collaborated with over 60 experts from around the world to provide gastroenterologists and those in training with the necessary information to successfully manage the patient with Crohn’s disease. Sections Include: • General o The role of the FDA in drug development; pediatric considerations; disease modifiers; and more • Medications o Antibiotic use in treatment of CD; oral budesonide; infliximab; novel biological and non biologic therapies for CD; and more • Specific Clinical Scenarios o Management of steroid unresponsive CD; management of enteric fistulae; use of pre- and probiotics; medical management of short bowel syndrome; maintenance therapy of CD; and more Features: • Color images, graphs, and tables • Extensive index that includes cross-referencing to Ulcerative Colitis: The Complete Guide to Medical Management • An appendix on Infliximab treatment • Comprehensive references at the end of each chapter Organized into an easy-to-reference format, Crohn’s Disease: The Complete Guide to Medical Management threads theory into practice and provides Gastroenterology professionals with the most comprehensive information available on this disease state. The other side of inflammatory bowel disease is covered in Drs. Gary R. Lichtenstein and Ellen J. Scherl’s Ulcerative Colitis: The Complete Guide to Medical Management. All gastroenterologists will find both books to be essential for future practice in the treatment and care of their patients with either Crohn’s disease or ulcerative colitis, as well as in the overall management of those with inflammatory bowel disease.
In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy. As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms. Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.